Bone · FDA Approved
Teriparatide (Forteo)
FDA-approved
01 · Overview
A recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When given intermittently by daily subcutaneous injection, teriparatide stimulates bone formation more than bone resorption, producing a net anabolic effect on bone.
It acts on the PTH1 receptor on osteoblasts. In its pivotal trial it increased bone mineral density at the spine, hip and whole body (PMID 11346808).
02 · Research summary & key findings
FDA-approved (Forteo, 2002) for osteoporosis in patients at high fracture risk (PMID 36111201). The Fracture Prevention Trial in postmenopausal women with prior vertebral fractures found a 65% relative reduction in new vertebral fractures and roughly a 53% reduction in nonvertebral fragility fractures at the lower of the two doses tested (PMID 11346808). The original label carried a boxed osteosarcoma warning and a 2-year lifetime limit based on high-dose rat studies; after large surveillance studies found no increase in human osteosarcoma, the boxed warning was removed and the 2-year limit revised in 2020 (PMID 36111201) (PMID 32990990).
03 · Regulatory status
Teriparatide (Forteo) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Teriparatide (Forteo) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Teriparatide (Forteo) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (daily)
References
- [1]Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med, 2001. PMID 11346808
- [2]Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study J Bone Miner Res, 2021. PMID 32990990
- [3]Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates JBMR Plus, 2022. PMID 36111201
Primary literature
- PubMed: "Teriparatide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Teriparatide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Teriparatide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Bone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.